Phase II Study of Crizotinib in Japanese Patients with Advanced MET exon14 skipping mutation-positive or MET high gene copy number-positive non-small cell lung cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Sep 2019
Price : $35 *
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 09 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 26 Mar 2018 Status changed from not yet recruiting to recruiting.
- 21 Mar 2018 New trial record